Recent Chemotherapy Raises COVID-19-Related Mortality Risk for Patients With Thoracic Cancer
Chemotherapy administered within 3 months of a diagnosis of COVID-19 increased the risk of death in patients with thoracic cancer.
Related Articles
First-Line Rucaparib Maintenance Provides Long-Term Benefits in Newly Diagnosed Ovarian Cancer
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, shares post-progression and updated survival outcomes with frontline rucaparib maintenance in ovarian cancer.
The Critical Nature of Decision-Making in the Development of Phase 3 Clinical Trials
Randomized trials are widely recognized to play a pivotal role in the decision-making associated with the establishment of clinical guidelines.
Current Treatment Options in Third-line MCL
Experts on mantle cell lymphoma discuss third-line treatment options available for patients.
Durvalumab ± Tremelimumab + Chemotherapy in First-Line Metastatic NSCLC: 5-Year Overall Survival Update from the POSEIDON Study
Joshua K. Sabari, MD, reviews data from the 5-year overall survival update from the POSEIDON study investigating durvalumab, tremelimumab, and chemotherapy in first-line metastatic non–small…
Avutometinib Plus Defactinib Makes a Phase 3 Debut in Low-Grade Serous Ovarian Cancer
Premal Thaker, MD, MS, discusses how the RAMP-201 trial paved a way for the RAMP-301 trial of avutometinib/defactinib in low-grade serous ovarian cancer.
Revisit Every OncLive On Air Episode from March 2024
In case you missed any, below is a recap of every episode of OncLive On Air that aired in March 2024.
Quality Over Quantity: What Concierge Medicine Can Offer to Patients With Cancer and Employers
The current health care economy has driven many employers to self-funding models to offer affordable health care coverage to employees.
Study Provides a First Look at Oncologists’ Views on Ethical Implications of AI in Cancer Care
In a survey, over 200 oncologists agreed on how AI can be responsibly integrated into patient care and how to protect patients from hidden biases…
Lunning and Rutherford Detail Considerations for BV-AVD Use in Older Patients With Hodgkin Lymphoma
Drs Lunning and Rutherford discuss findings from the ECHELON-1 trial of BV-AVD in the cohort of patients with Hodgkin lymphoma over 60 years of age.
FDA Requires Boxed Warning for Risk of T-Cell Malignancies With Approved CAR T-Cell Therapies
The FDA has mandated that the boxed warning for all approved CAR T-cell therapies be updated to include the serious risk of T-cell malignancies.